Bifogade filer
Inify_Laboratories_PDMR_attachment_corrected_
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Euronext Growth Oslo |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
2026-01-30 09:30:37
Stockholm, Sweden, 30 January 2026, Reference is made to the stock exchange
announcement made by Inify Laboratories AB (publ.) (the "Company") on 27 January
2026 regarding allocation of new shares to primary insiders in the repair issue
announced by the Company on 9 December 2025 (the "Repair Issue").
The number of shares allocated to board member Martin Ingvar was incorrectly
stated as 67,132 in the announcement of 27 January 2026. The correct number of
shares allocated to Ingvar in the Repair Issue is 67,372. Consequently, Ingvar
will, subject to the completion of the Repair Issue, own 283,435 shares in the
Company. A corrected notification form for Ingvar is attached hereto.
For further information, please contact CEO, Fredrik Palm,
fredrik.palm@inify.com, or visit https://www.inify.com.
This information is subject to the disclosure requirements in the EU Market
Abuse Regulation (EU 596/2014 article 19) and section 5-12 of the Norwegian
Securities Trading Act.
###
The future of diagnostics
Inify Laboratories offers diagnostics through specialised laboratory services in
histopathology, with a focus on streamlining patient pathways. The company
performs clinical diagnostics in prostate cancer and gastroenterology, providing
an integrated service that spans from early sample handling to final diagnosis.
The laboratory system is scalable both in handling large volumes of patient
samples and for replicating in new locations.
Quality and response times are optimised in every step - from logistics to
tissue preparation and diagnosis - using a fully digital, standardised and AI
-assisted workflow. The diagnosis is always performed by a pathologist and is
assisted by Inify's proprietary AI, proven to have world-leading precision in
clinical evaluations. The entire workflow is supported by a tailor-made system
that also enables development to include additional diagnostic areas.
Inify Laboratories is an international group headquartered in Stockholm, Sweden,
with local laboratories in Sweden and the UK. The company's share is listed on
Euronext Growth Oslo (https://live.euronext.com/en/product/equities/SE0017486103
-MERK) under the ticker
INIFY. (https://live.euronext.com/en/product/equities/SE0017486103-MERK)